PubMed Health⌕ Search

Biomedical subjects

M A Volkova

Publications and source records attributed to M A Volkova.

At least 19 recordsLinked to original sources
PubMed1998

[An evaluation of the prognostic significance of antigen CD95(Fas/APO-1) expression on the cells of patients with a myelodysplastic syndrome, acute myeloid leukemia and chronic myeloleukemia].

AIM: The expression of CD95(Fas/APO-1) antigen was studied on bone marrow cells of 19 MDS patients, peripheral blood blast cells of 15 acute myeloid leukemia (AML) patients, blast cells and granulocytes of 68 patients with chronic myeloid leukemia (CML)--24 in chronic, 9 in accelerated phase and 35 in blastic crisis (BC)--by indirect surface immunofluorescence assay using flow cytometry (FACScan, Becton Dickinson, USA). RESULTS: CD95(Fas/APO-1) antigen was revealed on bone marrow cells of 8 out of 19 (36.8%) MDS patients; the percentage of antigen-positive cells was 38.1 +/- 19.2%; on 45.5 +/- 22.8% of cells in 6(45%) of 15 AML patients. Fas/APO-1 antigen was totally absent in CML chronic stage; its expression was found in 34% (12 of 35) of our patients with CML BC on peripheral blood blasts and in 56% (5 of 9) on peripheral blast cells of CML patients in acceleration phase. CONCLUSION: The data on overall survival of CD95-positive MDS patients suggest that the presence of Fas antigen is a favorable prognostic sign for patients with MDS. The patients from CD95-negative group represent a risk group both for survival and AML transformation. In CML BC group the survival does not depend upon Fas-antigen expression.

Acute Disease↗
PubMed1996

Translocation (2;3)(p13;q26) in two cases of myeloid malignancies. Acute myeloblastic leukemia (M2) and blastic phase of chronic myeloid leukemia.

Two cases of myeloid leukemias (acute [AML M2] and chronic [CMC]), blastic crisis, with identical t(2;3)(p13;q26) are described. These cases had some peculiarities: no significant decrease of blood thrombocyte count in the AML patient and high increase of blood thrombocyte count during blastic phase in the CML patient; dysplastic megakaryocytes in bone marrow and unfavorable course of the disease; and short remission (3 months) in AML and short chronic phase (8 months) in CML. Clinical and morphologic findings in patients with t(2;3)(p13;q26) resembled those in cases with 3q21q26 syndrome or with other chromosome rearrangements involving 3q21 or 3q26.

Adolescent↗
PubMed1996

[A comparative clinico-morphological analysis of acute myelo- and myelomonoblastic leukemias in children and adults].

Previous morphocytochemical, immunological and cytogenetic analyses of blast cells in 174 children and 188 adults admitted to Cancer Research Center have shown that compared to adults in children leukemic precursors belong to earlier stage of differentiation similar to polypotent cell. The analysis covered 2 FAB-variants of ANLL comparable by the number of patients and intensity of the given chemotherapy (M2 and M4 ANLL FAB variants). The study included 65 children (50 with M2 and 15 with M4 FAB variants) and 43 adults (26 with M2 and 17 with M4 FAB variants) given therapy of standard intensity in the regimen 3+7 and 2+5. The children more frequently demonstrated involvement of the liver, spleen and peripheral lymph nodes. The percentage of complete remissions in both groups was not significantly different. 2- and 3-year recurrence-free survival was similar in two age groups with M2 FAB variants of ANLL. However, in M4 variant in adults this survival made up 18% against 0% in children. The differences may arise from lower peroxidase activity in children than in adults. It is suggested that M4 FAB variant in adults may indicate better prognosis than in children. Therefore, therapy in children with M4 FAB ANLL variant should be intensified.

Adolescent↗
PubMed1995

[Megakaryocytic dysplasia in acute nonlymphoblastic leukemias].

Megakaryocytic dysplasia, platelet and megakaryocytic counts were measured in 87 ANLL patients. High megakaryocytic levels were registered in 16.1%, normal in 17.2%, low or negligible in the rest of the examinees. Half of the patients had dysplasia. Thrombocytopenia present in 93% of cases attested to ineffective proliferation of megakaryocytes. Increased number of megakaryocytes with signs of dysplasia occurred more commonly in M0- and M4- variants of ANLL universally in anomalies of chromosome 3 long arm with involvement of q21 and/or q26 segments and occasionally in combination with other chromosome disorders. Megakaryocytosis developed less frequently in patients with ANLL variant M2 with t (8;21) and did not correlate with granulocyte and erythroid cell dysplasia. Pronounced megakaryocytosis in combination with thrombocytosis emerged in 4 patients: 2 of them had typical anomalies of chromosome 3--inv3(q21q26) and dup (3q21q26), 1 had monosomy 7 and 1 normal karyotype. Potential mechanisms responsible for dysplasia of megakaryocytes in ANLL are considered.

Adolescent↗
PubMed1994

[Hairy-cell leukemia (a review of the literature and the authors' own data)].

Gene engineering interferon made in Russia (reaferon, realdiron) was given to 40 patients with hairy-cell leukemia. Complete and partial remissions were achieved in 56% and 28% of the patients, respectively. Minimum effect was reported in 3% of the cases. In 5 cases with primary resistance or recurrences the authors used pentostatin which produced complete remissions in all the five patients.

Adult↗
PubMed1993

[The comparative evaluation of the efficacy of different therapeutic plans in acute nonlymphocytic leukemias].

78 previously untreated patients with acute non-lymphoblastic leukemia (ANLL) were assigned to cytosar-anthracyclines therapeutic programs: 29 (group I) received daunorubicin and AraC, 18 (group II) aclacinomycin A and AraC, 12 (group III) the scheme 3 + 7 with 12 mg/m2 novantron instead of daunorubicin, 19 (group IV) the scheme 3 + 7 with 12 mg/m2 idarubicin and cytosar. Groups I-III comprised both prognostically favorable and unfavorable ANLL variants, group 4 patients had for the most part unfavorable prognosis (MO-M3). A mean age of the patients was 41-42. Complete remissions were observed in 17 (58.6%), 9 (50%), 10 (83.3%), 11 (57.9%) patients of groups I, II, III and IV, respectively. An initial course of the treatment produced complete remissions in 65%, 33%, 80% and 90.9% of them, respectively. A mean duration of cytostatic leukothrombocytopenia was the longest in groups III and IV (16-22 days). Nonhematological toxicity occurred in the form of enteropathy and hepatitis. During the remission induction and consolidation 76% of the deaths were caused by infection and hemorrhagic diathesis. The median remission lasted 17.5, 13.5 and 5 months in groups I, II and III, respectively, and was not reached in group IV because of continuing remission in 50% of the patients by the end of the follow-up period (14 months). A 2-year survival rate was observed in 25% (group I), 11% (group II), 30% (group III) and 40% (group IV).

Aclarubicin↗
PubMed1992

[Biochemical indicators of anthracycline sensitivity of blast cells from patients with hemoblastoses].

It was shown that accumulation of adriamycin (ADR) and its impact on DNA synthesis in the blast cells of patients with hemoblastosis studied under conditions of short-term incubation correlated with the antileukemic activity of anthracyclines. The combination of the two biochemical and pharmacological indices, i.e. the high levels of ADR accumulation and inhibition of DNA synthesis, is may useful in solving the problem on inclusion of the antibiotics to the schemes of combined chemotherapy of patients with hemoblastosis.

Blast Crisis↗
PubMed1991

[The results of using differentiated programs of therapy in acute lymphoblastic leukemia in adults].

Results of the treatment of 30 adult patients with acute lymphoblastic leukemia are analyzed. Before the treatment was commenced, the patients were distributed into groups with a favourable, intermediate and unfavourable prognosis depending on the signs previously defined by the authors. In the phase of induction and consolidation of a remission, the treatment intensity in these groups varied. The rate of complete remissions (CR) reached 70% in the whole group; provided Ph-positive ALLs were excluded from the analysis, it was 75%, the median duration of the CR amounted to 21 months, the projected 4-year relapse-free survival was 41%. In the group of historic control (31 patients treated in accordance with the unified program), these indicators were 58 and 69%, 18 months, and 21%, respectively. All the differences appeared statistically insignificant. In spite of the total treatment intensification, the rate of lethal outcomes did not rise during remission induction.

Adolescent↗
PubMed1990

[The combination of chronic lympholeukemia with other malignant neoplasms].

Altogether 23 patients examined for secondary tumors at the All-Union Cancer Research Center of the USSR AMS underwent a clinical analysis. The overwhelming majority of the patients (17) were subjected to surgical intervention. Of these, none of the patients developed any postoperative complications or showed progress of chronic lympholeukemia (CLL). No relationship was noted between cytostatic treatment of CLL and origin of second tumors. No correlation was revealed either between the duration of CLL treatment and the incidence of second tumors origin. The authors provide a brief review of the literature on the given problem. Give a summary of the statistics of the CLL incidence in other malignant neoplasms.

Aged↗